

MedImpact Managed Formulary Actions

RATIONALE OF CHANGES

Trade Relations Strategy

Approach based on a financial review to deliver low net cost opportunities through pharmaceutical manufacture agreement strategies while taking into consideration the expected market share shift, future pipeline products, member impact and plan impact.

Low Net Cost Strategy

Delivering cost-efficient and clinically appropriate formulary content to meet the pharmacy benefit management needs of MedImpact clients; including appropriate development of preferred drug lists with consideration of low net cost strategies that includes MAC lists, non-pharmaceutical manufacture agreement strategies, and other cost management tools.

Clinical/Safety Strategy

Delivering cost-efficient and clinically appropriate formulary content to promote member safety and savings through the evaluation of scientific evidence, standards of practice, peer-reviewed medical literature, clinical practice guidelines, and guidance from the U.S. Food and Drug Administration (FDA)/Center for Disease Control (CDC).

Regulatory Update

Formulary/utilization management changes to comply with federal and/or state statutes, regulations, rules and policy requirements that pertain to the administration of the pharmacy benefit.

LEGEND

Note: The drug names listed are for reference purposes and denote action on the chemical entity unless otherwise specified. Where generic and brand products for a chemical entity co exist, coverage and copayment for each will be a function of plan benefit design.

FORMULARY		UTILIZATION MANAGEMENT (UM)		OPTIONAL BENEFIT EXCLUSION
Formulary Status	Formulary Actions	UM Definition	UM Actions	Coverage for each category will be a function of plan benefit design. These products may be excluded on client benefits. Formulary and UM decisions only apply for clients who choose to provide coverage for these drug categories.
F = Formulary	C = Change	AGE = Age restriction	A = Add UM	Antiobesity
NF = Non-Formulary	E = Excluded drug from formulary	QL = Quantity Limit	D = Delete UM	Cosmetic Indications
E = Excluded	S = Sustain	ST = Step Therapy	C = Change UM	Dietary Supplements and Non-Drug Products
NC = Not covered		PA = Prior Authorization	E = Excluded drug from formulary	Drugs to Treat Impotency or Sexual Dysfunction
S = Specialty		HST= Hard Step (Step without grandfathering- member must try preferred agents)	S = Sustain UM	Infertility
Non-S = Non-Specialty				Medical Foods: Dietary supplements, Enteral Feeding, Infant formula
				Non-Self Administered Drug (NSA)
				Ostomy Supplies
				Class O = Over the Counter Products
				Class Q = Products that are neither drugs nor devices, such as dietary supplements (including prenatal and other vitamins), medical foods, herbal preparations, and bulk flavorings or colorants
				Diagnostics

Notice of Formulary Update

Effective January 1, 2026, the standard HLEX Test Benefit will transition to a 5 Tier structure, with Essential Health Benefits (EHB) allocated to Tier 1. As a result, all other formulary tiers will be adjusted upward by one tier. For instance:

- The current Tier 1 will transition to Tier 2
- The current Tier 2 will transition to Tier 3
- The current Tier 3 will transition to Tier 4
- The current Tier 4 will transition to Tier 5

The Formulary Action Grid enclosed shows current tiering, reflecting the configuration as of today. Please take these upcoming changes into consideration if your client has selected the standard 5 Tier Formulary effective from January 1, 2026.

Formulary Actions Effective: 10/01/2025											Rationale of Changes				
Drug Attributes							Formulary Status		Utilization Management						
							Marketplace (HIEX)		Portfolio High / HIEX						
Category	Brand Name	Generic Name	Strength	Dosage Form	Route	Brand Status	Current Status	Act on	Current Status	Action	COMMERCIAL	Committee Actions	Optional Benefit Exclusion	Optional Formulary Exclusion (PFL/HIEX)	Client Communication - Commercial/HIEX
ALLERGY	AZELASTINE HCL	AZELASTINE HCL	205.5 MCG	SPRAY/PUMP	NASAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	AZELASTINE HCL	AZELASTINE HCL	137 MCG	SPRAY/PUMP	NASAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							3	S=3	QL ST	D=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	CLARINEX-D 12 HOUR	DESLO RATADINE/PSEUDOEPHEDRINE	2.5-120 MG	TBMP 12HR	ORAL	SSB	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	DESLO RATADINE	DESLO RATADINE	5 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL ST	D=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	DESLO RATADINE	DESLO RATADINE	5 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL ST	D=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	DESLO RATADINE	DESLO RATADINE	2.5 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	FLUTICASONE PROPIONATE	FLUTICASONE PROPIONATE	50 MCG	SPRAY SUSP	NASAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL ST	D=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	LEVOCETIRIZINE DIHYDROCHLORIDE	LEVOCETIRIZINE DIHYDROCHLORIDE	2.5 MG/5ML	SOLUTION	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	MOMETASONE FUROATE	MOMETASONE FUROATE	50 MCG	SPRAY/PUMP	NASAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
							1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
ALLERGY	OLOPATADINE HCL	OLOPATADINE HCL	0.6 %	SPRAY/PUMP	NASAL	GENERIC	2	S=2	QL	A=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
BEHAVIORAL HEALTH - OTHER	BELSOMRA	SUVOREXANT	5 MG	TABLET	ORAL	SSB	2	S=2	QL	A=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
							2	S=2	QL	A=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
BEHAVIORAL HEALTH - OTHER	BELSOMRA	SUVOREXANT	10 MG	TABLET	ORAL	SSB	2	S=2	QL	A=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
							2	S=2	QL	A=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
BEHAVIORAL HEALTH - OTHER	BELSOMRA	SUVOREXANT	15 MG	TABLET	ORAL	SSB	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			
							3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			
BEHAVIORAL HEALTH - OTHER	CAPLYTA	LUMATEPERONE TOSYLATE	42 MG	CAPSULE	ORAL	SSB	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			
							3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			
BEHAVIORAL HEALTH - OTHER	CAPLYTA	LUMATEPERONE TOSYLATE	10.5 MG	CAPSULE	ORAL	SSB	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025			
							3	C=2	QL ST	S=QL C=ST	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
BEHAVIORAL HEALTH - OTHER	DAYVIGO	LEMBOREXANT	5 MG	TABLET	ORAL	SSB	3	C=2	QL ST	S=QL C=ST	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
							3	C=2	QL ST	S=QL C=ST	Trade Relations Strategy	FBRC JULY 2025			ST: TRIAL OF ZOLPIDEM TARTRATE, ESZOPICLONE, OR ZALEPLON IN THE LAST 130 DAYS
BEHAVIORAL HEALTH - OTHER	ONYDA XR	CLONIDINE HCL	0.1 MG/ML	SUS ER 24H	ORAL	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
							3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	QELBREE	VILOXAZINE HCL	100 MG	CAP ER 24H	ORAL	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
							3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			

BEHAVIORAL HEALTH - OTHER	QELBREE	VILOXAZINE HCL	200 MG	CAP ER 24H	ORAL	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	SUNOSI	SOLRIAMFETOL HCL	75 MG	TABLET	ORAL	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
BEHAVIORAL HEALTH - OTHER	SUNOSI	SOLRIAMFETOL HCL	150 MG	TABLET	ORAL	SSB	3	C=2	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
BEHAVIORAL HEALTH - OTHER	VYLEESI	BREMELANOTIDE ACETATE	1.75MG/0.3	AUTO INJECT	SUBCUTANE.	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	XELSTRYM	DEXTROAMPHETAMINE	13.5MG/9HR	PATCH TD24	TRANSDERM.	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	XELSTRYM	DEXTROAMPHETAMINE	18 MG/9 HR	PATCH TD24	TRANSDERM.	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	XELSTRYM	DEXTROAMPHETAMINE	4.5 MG/9HR	PATCH TD24	TRANSDERM.	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
BEHAVIORAL HEALTH - OTHER	XELSTRYM	DEXTROAMPHETAMINE	9 MG/9 HR	PATCH TD24	TRANSDERM.	SSB	3	S=3	AGE QL ST	D=AGE S=QL S=ST	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - CARDIAC STIMULANT	CARISOPRODOL	CARISOPRODOL	350 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - HYPERTENSION	NORLIQVA	AMLODIPINE BESYLATE	1 MG/ML	SOLUTION	ORAL	SSB	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - HYPERTENSION	SPIRONOLACTONE	SPIRONOLACTONE	25 MG/5 ML	ORAL SUSP	ORAL	GENERIC	E	C=1	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - HYPERTENSION	TEZRLUY	TERAZOSIN HCL	1 MG/ML	SOLUTION	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - HYPERTENSION	VECAMYL	MECAMYLAMINE HCL	2.5 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	CAMZYOS	MAVACAMTEN	2.5 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	CAMZYOS	MAVACAMTEN	5 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	CAMZYOS	MAVACAMTEN	10 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	CAMZYOS	MAVACAMTEN	15 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	VERQUIVO	VERICIGUAT	2.5 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	VERQUIVO	VERICIGUAT	5 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
CARDIOVASCULAR DISEASE - MISCELLANEOUS AGENTS	VERQUIVO	VERICIGUAT	10 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
DERMATOLOGY - ACNE	DAPSONE	DAPSONE	7.50%	GEL W/PUMP	TOPICAL	GENERIC	1	S=1	ST	D=ST	Low Net Cost/Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
DERMATOLOGY - ANTINFLAMMATORY	OPZELURA	RUXOLITINIB PHOSPHATE	1.5 %	CREAM (G)	TOPICAL	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
DERMATOLOGY - ANTINFLAMMATORY	ZORYVE	ROFLUMILAST	0.15 %	CREAM (G)	TOPICAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
DERMATOLOGY - MISCELLANEOUS	YCANTH	CANTHARIDIN	0.7 %	SOL W/APPL	TOPICAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			

DERMATOLOGY - PSORIASIS/ECZEMA	BIMZELX	BIMEKIZUMAB-BKZX	160 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	BIMZELX	BIMEKIZUMAB-BKZX	320 MG/2ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	BIMZELX AUTOINJECTOR	BIMEKIZUMAB-BKZX	160 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	BIMZELX AUTOINJECTOR	BIMEKIZUMAB-BKZX	320 MG/2ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX	SECUKINUMAB	125 MG/5ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX (2 SYRINGES)	SECUKINUMAB	150 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX SENSOREADY (2 PENS)	SECUKINUMAB	150 MG/ML	PEN INJECTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX SYRINGE	SECUKINUMAB	75MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	COSENTYX UNOREADY PEN	SECUKINUMAB	300 MG/2ML	PEN INJECTR	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	ENSTILAR	CALCIPOTRIENE/BETAMETHASONE	0.005-.064	FOAM	TOPICAL	SSB	3	C=2	ST	D=ST	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	ILUMYA	TILDRAKIZUMAB-ASMN	100 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
DERMATOLOGY - PSORIASIS/ECZEMA	SILIQ	BRODALUMAB	210 MG/1.5	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
DERMATOLOGY - PSORIASIS/ECZEMA	VTAMA	TAPINAROF	1%	CREAM (G)	TOPICAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
DIABETES	CONTOUR NEXT TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR NEXT TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR NEXT TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR PLUS TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	CONTOUR TEST STRIP	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	C=2	QL ST	D=ST S=QL	Trade Relations Strategy	FBRC JULY 2025	Class O		QL: LIMITED TO 200 TEST STRIPS PER 30 DAYS
DIABETES	NON-PREFERRED STRIPS	BLOOD SUGAR DIAGNOSTIC		STRIP	MISCELL.	NON DRUG	3	S=3	QL ST	S=QL C=ST	Trade Relations Strategy	FBRC JULY 2025	Class O		ST: FREESTYLE, PRECISION, ASCENSIA PREFERRED. MBR TO OBTAIN FREE METER. FREESTYLE/PRECISION (BIN#510020; GROUP#98992432; ID:ERWMEDEWFORM) ASCENSIA (BIN#01884; PCN 3F; GROUP# MGDCARE; ID:CNMC7249802)
DIABETES	SIMPLERA SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
DIABETES	SIMPLERA SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
DIABETES	SIMPLERA SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			

DIABETES	SIMPLERA SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
DIABETES	SIMPLERA SYNC SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
DIABETES	SIMPLERA SYNC SENSOR	BLOOD-GLUCOSE SENSOR		EACH	MISCELL.	NON DRUG	E	C=3	E	A=PA	Clinical/Safety Strategy	P&T 3Q25			
ELECTROLYTE REGULATION	VELTASSA	PATROMER CALCIUM SORBITE	8.4 GRAM	POWD PACK	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
ELECTROLYTE REGULATION	VELTASSA	PATROMER CALCIUM SORBITE	16.8 GRAM	POWD PACK	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
ELECTROLYTE REGULATION	VELTASSA	PATROMER CALCIUM SORBITE	25.2 GRAM	POWD PACK	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
ELECTROLYTE REGULATION	VELTASSA	PATROMER CALCIUM SORBITE	1 G	POWD PACK	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
ENDOCRINE DISORDER - OTHER	INCORELEX	MECASERMIN	10 MG/ML	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
ENDOCRINE DISORDER - OTHER	OSENVELT	DENOSUMAB-BMW	120 MG/1.7	VIAL	SUBCUTANE.	SSB	E	C=4	E	A=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
ENDOCRINE DISORDER - OTHER	STOBOCLO	DENOSUMAB-BMW	60 MG/ML	SYRINGE	SUBCUTANE.	SSB	E	C=4	E	A=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
EYE - GENERAL DISORDERS	UPNEEQ	OXYMETAZOLINE HCL/PF	0.1 %	DROPERETTE	OPHTHALMIC	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ALVAIZ	ELTROMBOPAG CHOLINE	18 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ALVAIZ	ELTROMBOPAG CHOLINE	9 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ALVAIZ	ELTROMBOPAG CHOLINE	36 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ALVAIZ	ELTROMBOPAG CHOLINE	54 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	25 MCG/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	40 MCG/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	60 MCG/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	100 MCG/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	200 MCG/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	10MCG/0.4	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	40 MCG/0.4	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	60 MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBETOETIN ALFA IN POLYSORBAT	100MCG/0.5	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			

HEMATOLOGICAL DISORDERS	ARANESP	DARBEOETIN ALFA IN POLYSORBAT	150MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBEOETIN ALFA IN POLYSORBAT	500 MCG/ML	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBEOETIN ALFA IN POLYSORBAT	200MCG/0.4	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBEOETIN ALFA IN POLYSORBAT	25MCG/0.42	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ARANESP	DARBEOETIN ALFA IN POLYSORBAT	300MCG/0.6	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	DOPTelet	AVATROMBOPAG MALEATE	20 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	25 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	50 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	75 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	12.5 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	25 MG	POWD PACK	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	ELTROMBOPAG OLAMINE	ELTROMBOPAG OLAMINE	12.5 MG	POWD PACK	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	2000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	4000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	10000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	3000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	EPOGEN	EPOETIN ALFA	20000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	FABHALTA	IFTACOPAN HCL	200 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	JESDUVROQ	DAPRODUSTAT	1 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	JESDUVROQ	DAPRODUSTAT	2 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	JESDUVROQ	DAPRODUSTAT	4 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	JESDUVROQ	DAPRODUSTAT	6 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	JESDUVROQ	DAPRODUSTAT	8 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	30 MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			

HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	120MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	50 MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	75 MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	100MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	150MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	MIRCERA	METHOXY PEG-EPOETIN BETA	200MCG/0.3	SYRINGE	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	500 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	250 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	NPLATE	ROMIPLOSTIM	125 MCG	VIAL	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25	Non-Self Administered Drug (NSA)		
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	2000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	4000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	10000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	3000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	20000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	PROCRT	EPOETIN ALFA	40000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	2000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	3000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	4000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	10000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	40000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	20000/2ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	RETACRIT	EPOETIN ALFA-EPBX	20000/ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	TAVALISSE	FOSTAMATINIB DISODIUM	100 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	TAVALISSE	FOSTAMATINIB DISODIUM	150 MG	TABLET	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			

HEMATOLOGICAL DISORDERS	VAFSEO	VADADUSTAT	150 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
HEMATOLOGICAL DISORDERS	VAFSEO	VADADUSTAT	300 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	1 G/10 ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	1 G/10 ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	2.5G/25ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	5 G/50 ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	5 G/50 ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	10 G/100ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	10 G/100ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	20 G/200ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	20 G/200ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
IMMUNIZATION	GAMUNEX-C	IMMUNE GLOBUL G/GLY/IGA AVG 46	40 G/400ML	VIAL	INJECTION	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	Ad-Hoc Formulary Maintenance			
INFECTIOUS DISEASE - BACTERIAL	BAXDELA	DELAFOXACIN MEGGLUMINE	450 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
INFECTIOUS DISEASE - BACTERIAL	NUZYRA	OMADACYCLINE TOSYLATE	150 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
INFECTIOUS DISEASE - BACTERIAL	XENLETA	LEFAMULIN ACETATE	600 MG	TABLET	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
INFECTIOUS DISEASE - MISCELLANEOUS	XIFAXAN	RIFAXIMIN	550 MG	TABLET	ORAL	SSB	2	S=2	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
INFLAMMATORY DISEASE	AVSOLA	INFLIXIMAB-AXXQ	100 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	CIMZIA	CERTOLIZUMAB PEGOL	400 MG/2ML	SYRINGEKIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	CIMZIA (2 PACK)	CERTOLIZUMAB PEGOL	400 MG	KIT	SUBCUTANE.	SSB	4	S=4	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	DUROLANE	HYALURONATE SODIUM, STABILIZED	60 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	EUFLEXXA	HYALURONATE SODIUM	20 MG/2 ML	SYRINGE	INTRAARTIC	SSB	2	S=2	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	EUFLEXXA	HYALURONATE SODIUM	20 MG/2 ML	SYRINGE	INTRAARTIC	SSB	2	S=2	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	GEL-ONE	HYALURONATE SOD, CROSS-LINKED	30 MG/3 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	GELSYN-3	HYALURONATE SODIUM	16.8MG/2ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		

INFLAMMATORY DISEASE	GENVISC 850	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	HYALGAN	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	HYALGAN	HYALURONATE SODIUM	10 MG/ML	VIAL	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	INFLIXIMAB	INFLIXIMAB	100 MG	VIAL	INTRAVEN.	GENERIC	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	MONOVISC	HYALURONATE SODIUM, STABILIZED	88 MG/4 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	125 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	50MG/0.4ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT	87.5MG/0.7	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	ORENCIA	ABATACEPT/MALTOSE	250 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	ORENCIA CLICKJECT	ABATACEPT	125 MG/ML	AUTO INJECT	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	ORTHOVISC	HYALURONATE SODIUM	30 MG/2 ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	RENFLIXIS	INFLIXIMAB-ABDA	100 MG	VIAL	INTRAVEN.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SIMPONI	GOLIMUMAB	50MG/0.5ML	PEN INICTR	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	SIMPONI	GOLIMUMAB	50MG/0.5ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	SIMPONI	GOLIMUMAB	100 MG/ML	SYRINGE	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	SIMPONI	GOLIMUMAB	100 MG/ML	PEN INICTR	SUBCUTANE.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025			
INFLAMMATORY DISEASE	SIMPONI ARIA	GOLIMUMAB	50 MG/4 ML	VIAL	INTRAVEN.	SSB	4	S=4	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SODIUM HYALURONATE	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SODIUM HYALURONATE	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SUPARTZ FX	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SYNJOINT	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SYNVISC	HYLAN G-F 20	10MG/2ML	SYRINGE	INTRAARTIC	SSB	2	S=2	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	SYNVISC-ONE	HYLAN G-F 20	48 MG/6 ML	SYRINGE	INTRAARTIC	SSB	2	S=2	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	TRILURON	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C+PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		

INFLAMMATORY DISEASE	TRIVISC	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
INFLAMMATORY DISEASE	VISCO-3	HYALURONATE SODIUM	10 MG/ML	SYRINGE	INTRAARTIC	SSB	3	S=3	PA	C=PA	Trade Relations Strategy	FBRC JULY 2025	Non-Self Administered Drug (NSA)		
MISCELLANEOUS AGENTS	AUVI-Q	EPINEPHRINE	0.3MG/0.3	AUTO INJECT	INJECTION	SSB	3	C=2	E	A=QL	Trade Relations Strategy	FBRC JULY 2025			QL: LIMITED TO 2 AUTO-INJECTORS PER 365 DAYS
MISCELLANEOUS AGENTS	AUVI-Q	EPINEPHRINE	0.3MG/0.3	AUTO INJECT	INJECTION	SSB	3	C=2	E	A=QL	Trade Relations Strategy	FBRC JULY 2025			QL: LIMITED TO 2 AUTO-INJECTORS PER 365 DAYS
MISCELLANEOUS AGENTS	AUVI-Q	EPINEPHRINE	0.15/0.15	AUTO INJECT	INJECTION	SSB	3	C=2	E	A=QL	Trade Relations Strategy	FBRC JULY 2025			QL: LIMITED TO 2 AUTO-INJECTORS PER 365 DAYS
MISCELLANEOUS AGENTS	AUVI-Q	EPINEPHRINE	0.15/0.15	AUTO INJECT	INJECTION	SSB	3	C=2	E	A=QL	Trade Relations Strategy	FBRC JULY 2025			QL: LIMITED TO 2 AUTO-INJECTORS PER 365 DAYS
MISCELLANEOUS AGENTS	AUVI-Q	EPINEPHRINE	0.1MG/.1ML	AUTO INJECT	INJECTION	SSB	3	C=2	E	A=QL	Trade Relations Strategy	FBRC JULY 2025			QL: LIMITED TO 2 AUTO-INJECTORS PER 365 DAYS
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	5 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	10 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	2.5 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	7.5 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	2 MG	TAB SUSP	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	3 MG	TAB SUSP	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEOPLASTIC DISEASE	EVEROLIMUS	EVEROLIMUS	5 MG	TAB SUSP	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
NEUROLOGICAL DISEASE - MISCELLANEOUS	SKYCLARYS	OMAVELOXOLONE	50 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
OTHER DRUGS	ZELSUVMI	BERDAZIMER SODIUM	10.3%	GEL (GRAM)	TOPICAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	DIACOMIT	STRIPENTOL	250 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	DIACOMIT	STRIPENTOL	500 MG	CAPSULE	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	DIACOMIT	STRIPENTOL	250 MG	POWD PACK	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	DIACOMIT	STRIPENTOL	500 MG	POWD PACK	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	EPIDIOLEX	CANNABIDIOL (CBD)	100 MG/ML	SOLUTION	ORAL	SSB	4	S=4	ST	C=ST	Clinical/Safety Strategy	P&T 3Q25			ST: TRIAL OF ONE OF THE FOLLOWING GENERIC ANTICONSULVANTS: CLOBAZAM, VALPROIC ACID DERIVATIVES, LAMOTRIGINE, LEVETIRACETAM, TOPIRAMATE, VIGABATRIN, CARBAMAZEPINE, AND OXCARBAZEPINE IN THE LAST 365 DAYS
SEIZURE DISORDER	EPONTIA	TOPIRAMATE	25 MG/ML	SOLUTION	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	FELBAMATE	FELBAMATE	600 MG/5ML	ORAL SUSP	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	FELBAMATE	FELBAMATE	400 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			

SEIZURE DISORDER	FELBAMATE	FELBAMATE	600 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	FINTEPLA	FENFLURAMINE HCL	2.2 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LACOSAMIDE	LACOSAMIDE	50 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LACOSAMIDE	LACOSAMIDE	100 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LACOSAMIDE	LACOSAMIDE	150 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LACOSAMIDE	LACOSAMIDE	200 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LACOSAMIDE	LACOSAMIDE	10 MG/ML	SOLUTION	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMICTAL XR (BLUE)	LAMOTRIGINE	25(21)-50	TB ER DSPK	ORAL	SSB	3	S=3	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMICTAL XR (GREEN)	LAMOTRIGINE	50-100-200	TB ER DSPK	ORAL	SSB	3	S=3	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMICTAL XR (ORANGE)	LAMOTRIGINE	25-50-100	TB ER DSPK	ORAL	SSB	3	S=3	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	25 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	50 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	100 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	200 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	300 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ER	LAMOTRIGINE	250 MG	TAB ER 24	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT	LAMOTRIGINE	50 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT	LAMOTRIGINE	25 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT	LAMOTRIGINE	100 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT	LAMOTRIGINE	200 MG	TAB RAPDIS	ORAL	GENERIC	1	S=1	QL ST	D=ST D=QL	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT (BLUE)	LAMOTRIGINE	25(21)-50	TB RD DSPK	ORAL	GENERIC	1	S=1	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT (GREEN)	LAMOTRIGINE	50(42)-100	TB RD DSPK	ORAL	GENERIC	1	S=1	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	LAMOTRIGINE ODT (ORANGE)	LAMOTRIGINE	25-50-100	TB RD DSPK	ORAL	GENERIC	1	S=1	ST	D=ST	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	MOTPOLY XR	LACOSAMIDE	100 MG	CAP ER 24H	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			

SEIZURE DISORDER	MOTPOLY XR	LACOSAMIDE	150 MG	CAP ER 24H	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	MOTPOLY XR	LACOSAMIDE	200 MG	CAP ER 24H	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	RUFINAMIDE	RUFINAMIDE	40 MG/ML	ORAL SUSP	ORAL	GENERIC	1	S=1	QL ST	S=QL C=ST	Clinical/Safety Strategy	P&T 3Q25			ST: TRIAL OF VALPROIC ACID OR DIVALPROEX OR CLOBAZAM IN THE PAST 120 DAYS
SEIZURE DISORDER	RUFINAMIDE	RUFINAMIDE	200 MG	TABLET	ORAL	GENERIC	1	S=1	QL ST	S=QL C=ST	Clinical/Safety Strategy	P&T 3Q25			ST: TRIAL OF VALPROIC ACID OR DIVALPROEX OR CLOBAZAM IN THE PAST 120 DAYS
SEIZURE DISORDER	RUFINAMIDE	RUFINAMIDE	400 MG	TABLET	ORAL	GENERIC	1	S=1	QL ST	S=QL C=ST	Clinical/Safety Strategy	P&T 3Q25			ST: TRIAL OF VALPROIC ACID OR DIVALPROEX OR CLOBAZAM IN THE PAST 120 DAYS
SEIZURE DISORDER	VIGABATRIN	VIGABATRIN	500 MG	TABLET	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	VIGADRONE	VIGABATRIN	500 MG	POWD PACK	ORAL	GENERIC	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	VIGAFYDE	VIGABATRIN	100 MG/ML	SOLUTION	ORAL	SSB	4	S=4	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SEIZURE DISORDER	ZONISADE	ZONISAMIDE	100 MG/5ML	ORAL SUSP	ORAL	SSB	3	S=3	PA	C=PA	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	10 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	20 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	BACLOFEN	BACLOFEN	5 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	CARISOPRODOL	CARISOPRODOL	250 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	CHLORZOXAZONE	CHLORZOXAZONE	500 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	5 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	10 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	CYCLOBENZAPRINE HCL	CYCLOBENZAPRINE HCL	7.5 MG	TABLET	ORAL	GENERIC	E	C=1	E	NONE	Clinical/Safety Strategy	P&T 3Q25		FDA Approved Non-Essential	
SKELETAL MUSCLE DISORDER	DANTROLENE SODIUM	DANTROLENE SODIUM	25 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	DANTROLENE SODIUM	DANTROLENE SODIUM	100 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	DANTROLENE SODIUM	DANTROLENE SODIUM	50 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	METAXALL	METAXALONE	800 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	METAXALONE	METAXALONE	400 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	METHOCARBAMOL	METHOCARBAMOL	500 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	METHOCARBAMOL	METHOCARBAMOL	750 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			

SKELETAL MUSCLE DISORDER	ORPHENADRINE CITRATE ER	ORPHENADRINE CITRATE	100 MG	TABLET ER	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	2 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	4 MG	TABLET	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	2 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	4 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			
SKELETAL MUSCLE DISORDER	TIZANIDINE HCL	TIZANIDINE HCL	6 MG	CAPSULE	ORAL	GENERIC	1	S=1	QL	D=QL	Clinical/Safety Strategy	P&T 3Q25			